
ATC Code ^a		
N05AL05	Amisulpride	
N05AX12	Aripiprazole	
N05AH02	Clozapine	
N05AH03	Olanzapine	
N05AX08	Risperidone	
N05AA01	Chlorpromazine	
N05AD08	Droperidol	
N05AF01	Flupentixol	
N05AB02	Fluphenazine	
N05AD01	Haloperidol	
N05AH01	Loxapine	
N05AG03	Penfluridol	
N05AC01	Periciazine	
N05AB03	Perphenazine	
N05AG02	Pimozide	
N05AD05	Pipampérone	
N05AC04	Pipotiazine	
N05AL01	Sulpiride	
N05AL03	Tiapride	
N05AF05	Zuclopenthixol	

Appendix 1 Antipsychotics included in the study

^aATC: anatomical-therapeutic-chemical

Appendix 2 Percentage of the cohort members who discontinued their antidepressant treatment according to various definition of early discontinuation (Marseilles, France - n=14518 individuals)



* within the 6 months following the new antidepressant treatment.

Appendix 3 Individual and prescriber factors associated with early discontinuation of antidepressant treatment: results of the sensitivity analysis using an interval defining a new antidepressant treatment as 1 year without antidepressant treatment (Marseilles, France – n=5998 individuals: n=1130 prescribers)

n=5998 individuals; n=1130 prescribers)	

	n	Adjusted RR ^a	95% Cls ^a
Individual level			
CMUC coverage ^b (reference: no)	1296	1.11	1.07-1.15
Type of antidepressant treatment (reference:			
SSRIs ^c)			
Tricyclics and monoamine oxidase inhibitors	477	1.15	1.08-1.20
Miscellaneous other antidepressants	1604	1.04	1.00-1.08
Other cases (\geq 2 types of antidepressant)	24	1.02	.69-1.23
Prescriber level			
Percentage of CMUC-covered patients ^b (%,			
reference: <5)			
5-23	2948	1.02	.94-1.09
>23	2215	1.09	.98-1.19

^a Estimated odds ratio were corrected with the method of Zhang and Yu to estimate relative risks (RR) with their 95% confidence intervals (CIs). Results of multilevel logistic regression analyses adjusted for 1) individual level: gender, age number of consultations with private general practitioners and psychiatrists in 2008-2009, chronic somatic illness, chronic psychiatric illness, coprescription of antipsychotics and/or lithium, coprescription of anxiolytics and/or hypnotic; 2) prescriber level: gender, age, annual mean expenditure due to medication prescriptions dispensed/patient in 2008-2009, percentage of patients aged 60 years or more, percentage of patients with chronic illness.

^b CMUC: Couverture maladie universelle complémentaire (Complementary Universal Health Insurance program covering persons with very low income.

^c SSRIs: Selective serotonin re-uptake inhibitors.

Appendix 4 Individual and prescriber factors associated with early discontinuation of antidepressant treatment: results of the sensitivity analysis using two different definitions of early discontinuation of new antidepressant treatment (Marseilles, France - n=14518 individuals; n=1437 prescribers)

	n	Adjusted RR ^a	95% Cls ^a
EARLY DISCONTINUATION = NO ANTIDEPRESSANT R ANTIDEPRESSANT TREATMENT ^b	EFILL WITHIN ⁻	THE 6 MONTHS FOLLOWING	THE NEW
Individual level			
CMUC coverage ^c (reference: no)	3189	1.13	1.07-1.18
Type of antidepressant treatment (reference: SSRIs ^d)			
Tricyclics and monoamine oxidase	1165	1.18	1.10-1.26
inhibitors	1100	1.10	1.10 1.20
Miscellaneous other antidepressants or	2024	1.00	07 1 07
other cases (≥ 2 types of antidepressant) [®]	3831	1.02	.97-1.07
Prescriber level			
Percentage of CMUC-covered patients ^c			
(%, reference: <5)			
5-23	7164	1.09	1.00-1.18
>23	5348	1.27	1.13-1.41
EARLY DISCONTINUATION = <6 CLAIMS WITHIN THE TREATMENT ^b	6 MONTHS FO	LLOWING THE NEW ANTIDEF	PRESSANT
	0.400		
CMUC coverage ^c (reference: no)	3189	1.07	1.06-1.09
Type of antidepressant treatment			
(reference: SSRIs ^ª) <i>Tricyclics and monoamine oxidase</i>			
inhibitors	1165	1.09	1.07-1.11
Miscellaneous other antidepressants	3755	1.02	1.00-1.03
Other cases (≥ 2 types of	76	.84	.6996
antidepressant)			.00.00
Prescriber level			
Percentage of CMUC-covered patients ^c			
(%, reference: <5)			
5-23	7164	1.01	.97-1.04
>23	5348	1.07	1.02-1.11

95% confidence intervals (CIs). Results of multilevel logistic regression analyses adjusted for 1) individual level: gender, age number of consultations with private general practitioners and psychiatrists in 2008-2009, chronic somatic illness, chronic psychiatric illness, coprescription of antipsychotics and/or lithium, coprescription of anxiolytics and/or hypnotic; 2) prescriber level: gender, age, annual mean expenditure due to medication prescriptions dispensed/patient in 2008-2009, percentage of patients aged 60 years or more, percentage of patients with chronic illness.

^b New antidepressant treatment: no antidepressant claim in the 6 months before the index claim.

^c CMUC: Couverture maladie universelle complémentaire (Complementary Universal Health Insurance program covering persons with very low income.

^d SSRIs: Selective serotonin re-uptake inhibitors.

^e The categories "Miscellaneous other antidepressants" and "Other cases (≥ 2 types of antidepressant)" have been merged because no case of discontinuation was found in the latter category.